Rotundine

Rotundine Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  The roots of Stephania rotunda furnish this alkaloid which forms colourless plates when crystallized from EtOH. It is laevorotatory with [α]²³_D - 262° (EtOH) and gives a crystalline hydrochloride with m.p. 258-9°C (dec.) and the methiodide which decomposes at that same temperature. Three methoxyl groups and one methyl group are present.

• Physikalische Eigenschaften

  Appearance: off-white solid, odorless, tasteless, and turns yellow under light and heat. It should be protected from light and air. Solubility: this product is usually dissolved in chloroform, slightly soluble in ethanol or ether, insoluble in water, and soluble in dilute sulfuric acid. Melting point: 141–144?°C. Specific optical rotation: ?290 to –300°.

• History

  From the 1920s, many researchers have focused on the alkaloid compounds contained in the Yan Hu Suo and extracted more than 30 different kinds of alkaloids. Among them Rotundine is one of the most important active compounds and has been successfully applied in clinical practice.
  Tetrahydropalmatine (THP) was firstly discovered by Zhao Chenggu, a famous medicinal phytochemist in China. He isolated 13 kinds of alkaloids and identified the structure of 6 of them. In 1936, Huang Minglong, a famous organic chemist, proved THP is a racemate. From 1933, Wang Jingxi and Lu Zihui began to study the pharmacological effects of THP and found that THP could induce catalepsy in animals. Rotundine is a levo-THP and obtained from the resolution of DL-THP during 1959–1964. From 1956 to 1965, the famous Chinese neuropharmacologist, Jin Guozhang, identified Rotundine as the main effective component in Yan Hu Suo and further studied its underlying mechanisms. He also found that Stephania contains abundant L-THP, which could become the source of clinical medication.
  In 1965, Rotundine was recorded in the textbooks of pharmacology. After over 20?years of clinical practices, people have proved that Rotundine has reliable efficacy and low side effect. In 1977, Rotundine was recorded in the Chinese Pharmacopoeia. In 1979, THP achieved a full synthesis, and currently Rotundine is mainly produced by artificial synthesis. From 1980, the study on the mechanisms of Rotundine made great progress. The analgesic effect of Rotundine has nothing to do with opioid receptors or prostaglandins. Rotundine does not belong to narcotic analgesics and antipyretic analgesics. Further, Rotundine has been found to have no affinity with M-cholinergic receptor and GABA system in the brain. But it has affinity to dopamine receptors. The exact mechanisms and pharmacology effects of Rotundine still need more research.

• Verwenden

  An analgesic drug found in Chinese herbal medicine, used to treat heart disease and liver damage.

• Definition

  ChEBI: 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline is an alkaloid.

• Pharmakologie

  1. Effects on the central nervous system: Rotundine has significant analgesic, sedative, and hypnotic effects, and its mechanism has nothing to do with opioid receptors. It has no obvious addiction effect. Using Rotundine combined with pethidine can enhance the analgesic effect, reduce the amount of pethidine, and further reduce the occurrence of drug dependence. The present study suggests that Rotundine is a central dopamine receptor blocker that inhibits the transmission of peripheral pain information by blocking the D2 receptor of the striatum and nucleus accumbens and the PAG-RgpI-spinal dorsal horn nerve pathway. In addition, Rotundine also has a suppression of the strengthening of the motor response induced by drug abuse, that is, inhibition of behavioral sensitization.
  2. Effects on the cardio-cerebrovascular system: Rotundine has inhibitory effect on the injuries caused by cerebral ischemia and reperfusion and myocardial ischemia and reperfusion. It also could lower the blood pressure. The pharmacological mechanism of Rotundine on the cardiovascular and cerebrovascular aspects is quite complex and may relate to the regulation of inflammation and inhibition of apoptosis. It is also found that Rotundine acts on α-receptors and has a noncompetitive antagonistic effect on calcium.
  3. Rotundine can reverse the drug resistance of tumor cells; the mechanism may be through the downregulating of the expression of P-glycoprotein (P-gp) and the upregulating of the expression of topo II in tumor cells.
  4. Rotundine has an excitatory effect on the endocrine system, such as the pituitaryadrenal system, and also has a protective effect on the liver.
  5. Drug metabolisms: The absorption of Rotundine by oral administration is complete. At 15?min it can be absorbed by 40–50%. It begins to work at 10–30?min, and the effect can last 2–5?h. In vivo distribution is through fat and the lung, liver, and kidney. If administered by subcutaneous injection, after 12?h, Rotundine will be discharged by 80% with the urine.

• Clinical Use

  1. Pain induced by gastrointestinal and hepatobiliary disorders, menstrual pain, and pain after childbirth.
  2. Mild trauma and postoperative pain
  3. Headache insomnia and spasmodic cough.
  4. There is a report about the usage of Rotundine in arrhythmia caused by I–III hypertension and other diseases.
  5. The hypnotic effect of Rotundine happens in 15?min after administration and then appears after 2?h. Because the analgesic effect happens at the same time, Rotundine is particularly suitable for insomnia patients with pain.
  6. Side effects: drowsiness, dizziness, fatigue, and nausea. Large dose of Rotundine can inhibit the respiratory center and may cause extrapyramidal symptoms.

• target

  NOS | NO | D1 receptor | 5-HT1A | D2 receptor | D3 receptor

• läuterung methode

  Crystallise it from MeOH or EtOH by addition of water [see Kametani & Ihara J Chem Soc (C) 530 1967, Bradsher & Dutta J Org Chem 26 2231 1961]. When crystallised from Me2CO/Et2O, it has m 142o. The hydrate has m 115o(effervescence). The picrate has m 188o(dec) (from aqueous EtOH). [Bradsher & Datta J Org Chem 26 2231 1961, Beilstein 21 II 196, 21 III/IV 2769.]

• Einzelnachweise

  Kondo, Matsuno., J. Pharm. Soc., Japan, 64, (9A), 28 (1944)

Rotundine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(379)Suppliers

10097-84-4, Rotundine Verwandte Suche: